Compare CAKE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAKE | IMCR |
|---|---|---|
| Founded | 1972 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.7B |
| IPO Year | 1996 | 2016 |
| Metric | CAKE | IMCR |
|---|---|---|
| Price | $57.71 | $30.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 11 |
| Target Price | $59.47 | ★ $64.70 |
| AVG Volume (30 Days) | ★ 1.4M | 347.6K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $3,751,806,000.00 | $249,428,000.00 |
| Revenue This Year | $6.16 | $14.39 |
| Revenue Next Year | $6.60 | $8.19 |
| P/E Ratio | $18.52 | ★ N/A |
| Revenue Growth | 4.75 | ★ 43.05 |
| 52 Week Low | $43.00 | $23.15 |
| 52 Week High | $69.70 | $40.71 |
| Indicator | CAKE | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 39.51 |
| Support Level | $57.03 | N/A |
| Resistance Level | $64.18 | $34.86 |
| Average True Range (ATR) | 2.18 | 1.69 |
| MACD | -0.97 | -0.12 |
| Stochastic Oscillator | 9.90 | 10.94 |
The Cheesecake Factory Inc is a restaurant company that owns and operates multiple casual dining brands across the United States and Canada under brands that include The Cheesecake Factory, North Italia, Flower Child, and additional brands within its Fox Restaurant Concepts portfolio. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, Other FRC, and Other. The majority of the company's revenue comes from the Cheesecake Factory restaurants segment.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.